Q-omics provides the consensus-scored THOC5 profile across patient tissues and cancer cell-line models. THOC5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, THOC5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, THOC5 protein abundance shows 30,982 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where THOC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THOC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THOC5 survival associations across molecular data types. THOC5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THOC5 RNA expression–survival associations across cancer types. High THOC5 expression shows unfavorable associations in LIHC, ACC, KICH, MESO and COAD, but favorable associations in READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for THOC5 RNA expression.
This table summarizes THOC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for THOC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THOC5 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, THCA and LUAD. The HNSC box plot shows higher THOC5 RNA expression in tumor versus normal tissue (log2 FC = +0.894, t-test p < 0.001).
This table shows molecular features associated with THOC5 in patient tissues and cancer cell lines. In patient samples, THOC5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, THOC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
